Bristol Myers Squibb (BMY.US) experiences strong demand for new drugs! Q2 revenue beats expectations, significantly raises full-year 2026 guidance

```htmlAccording to Golden Ten Data APP, thanks to strong demand for new heart disease and cancer drugs, most of Bristol Myers Squibb's (BMY.US) drug portfolio exceeded Wall Street expectations in the second quarter, prompting the company to raise its full-year 2026 sales and profit forecasts. The financial report shows that in Q2, the company’s revenue reached $12.97 billion, a year-over-year increase of 5.7%, surpassing expectations by $1.23 billion; adjusted earnings per share were $2.04, beating expectations by $0.44.```